Changing paradigm in the treatment of amyloidosis: From disease-modifying drugs to anti-fibril therapy

Changing paradigm in the treatment of amyloidosis: From disease-modifying drugs to anti-fibril therapy

Cardiac amyloidosis is a rare, debilitating, and usually fatal disease increasingly recognized in clinical practice despite patients presenting with non-specific symptoms of cardiomyopathy. The current standard of care (SoC) focuses on preventing further amyloid formation and deposition, either with...

Full description

Bibliographic Details
Main Authors: C. Cristina Quarta, Marianna Fontana, Thibaud Damy, Julia Catini, Damien Simoneau, Michele Mercuri, Pablo Garcia-Pavia, Mathew S. Maurer, Giovanni Palladini
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-12-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
cardiac light chain amyloidosis
cardiac amyloidosis (CA)
cardiac amyloidosis—ATTR
standard of care (SoC)
treatment gaps
future treatments
Online Access:https://www.frontiersin.org/articles/10.3389/fcvm.2022.1073503/full

Internet

https://www.frontiersin.org/articles/10.3389/fcvm.2022.1073503/full

Similar Items